CIK 0001655759
- Accelerated filer
ARVINAS, INC.
Sign in to watch- Ticker
- ARVN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 472566120
- Phone
- +1 203-535-1456
- Business address
- 395 WINCHESTER AVE, 5 SCIENCE PARK, NEW HAVEN, CT, 06511
- Former names
- ARVINAS INC., ARVINAS HOLDING COMPANY, LLC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,475
- in 1 filing, $1K under 10b5-1 plans
Net −$1,475. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2018-10-01 | Margus Bradley Albert Director | Conversion · Series C Preferred Stock | −18,942 | 0 | ||
| 2018-10-01 | Cassidy Sean A Chief Financial Officer | Purchase | +1,600 | $16.00 | $26K | 169,465 |
| 2018-10-01 | Cassidy Sean A Chief Financial Officer | Conversion | +5,345 | 174,810 | ||
| 2018-10-01 | Cassidy Sean A Chief Financial Officer | Conversion · Series B Preferred Stock | −15,007 | 0 | ||
| 2018-10-01 | Cassidy Sean A Chief Financial Officer | Conversion · Series C Preferred Stock | −2,368 | 0 | ||
| 2018-10-01 | Loven Jakob Director | Purchase | +312,500 | $16.00 | $5.0M | 312,500 |
| 2018-10-01 | Loven Jakob Director | Conversion | +1,381,851 | 1,694,351 | ||
| 2018-10-01 | Loven Jakob Director | Conversion · Series C Preferred Stock | −4,491,018 | 0 | ||
| 2018-10-01 | Flynn James E 10% owner | Conversion | +307,078 | 307,078 | ||
| 2018-10-01 | Flynn James E 10% owner | Conversion | +307,078 | 307,078 | ||
| 2018-10-01 | Flynn James E 10% owner | Conversion | +307,078 | 307,078 | ||
| 2018-10-01 | Flynn James E 10% owner | Purchase | +104,167 | $16.00 | $1.7M | 411,245 |
| 2018-10-01 | Flynn James E 10% owner | Purchase | +104,167 | $16.00 | $1.7M | 411,245 |
| 2018-10-01 | Flynn James E 10% owner | Purchase | +104,166 | $16.00 | $1.7M | 411,244 |
| 2018-10-01 | Flynn James E 10% owner | Conversion · Series C Preferred Stock | −998,004 | 0 | ||
| 2018-10-01 | Flynn James E 10% owner | Conversion · Series C Preferred Stock | −998,004 | 0 | ||
| 2018-10-01 | Flynn James E 10% owner | Conversion · Series C Preferred Stock | −998,004 | 0 | ||
| 2018-09-26 | Kennedy Edward Moore Jr. Director | Grant or award · Stock Option (right to buy) | +32,870 | 32,870 | ||
| 2018-09-26 | Taylor Ian Senior Vice President, Biology | Grant or award · Stock Option (right to buy) | +23,390 | 23,390 | ||
| 2018-09-26 | Taylor Ian Senior Vice President, Biology | Grant or award · Stock Option (right to buy) | +2,600 | 2,600 |
Page 30 of 32 · 628 trades